Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.